Inappropriate ICD Shocks During Atrial Fibrillation With Rapid Ventricular Response
A 68-year-old man with ischemic cardiomyopathy (LVEF 30%) and a dual-chamber ICD implanted 2 years ago for secondary prevention takes apixaban for atrial fibrillation and amiodarone. While gardening he received two ICD shocks; he felt palpitations beforehand but did not lose consciousness. Interrogation shows DDDR mode, lower rate 60 bpm, VT zone at 160 bpm, VF zone at 200 bpm, and SVT discrimination enabled with nominal settings. Stored electrograms show an irregular ventricular rate of 165–175 bpm with fibrillatory atrial activity, and both shocks were delivered during this rhythm. His prior true VT was at 180 bpm and was terminated by ATP. He has no fever, chest pain, or pocket abnormality. Blood pressure is 132/80 mmHg; heart rate is 150 bpm and irregular. He asks whether the device is malfunctioning and whether the shocks can be prevented without losing protection from his VT.
1. Explain the most likely mechanism for the two shocks and why the programmed SVT discriminators did not withhold therapy.
Read the worked answer
The stored rhythm is atrial fibrillation with a rapid ventricular response, and the ventricular rate falls inside the programmed VT zone of 160 bpm. The device therefore treated a supraventricular rhythm as a ventricular tachyarrhythmia.
SVT discriminators are designed to separate sinus tachycardia, atrial fibrillation, and other supraventricular rhythms from VT, but they are not infallible. Nominal settings often rely on ventricular interval stability, onset, and sometimes far-field or morphology criteria. In atrial fibrillation, ventricular intervals are irregular, so stability criteria fail to classify the rhythm as SVT reliably. If the device has an atrial channel, it may recognize atrial fibrillation but still deliver therapy unless an AF/AFL suppression or atrial fibrillation rejection feature is specifically enabled and effective. The rate cutoff of 160 bpm is also relatively low and overlaps the patient's rapid AF. The shocks are therefore best explained by under-recognition of AF with RVR rather than by lead failure or random device malfunction.
The prior clinical VT at 180 bpm is important: simply raising the VT zone above the AF rate could delay therapy for a genuine VT that is only slightly faster. This is a programming trade-off, not a simple fix.
2. Recommend specific programming changes and non-device management, explaining the trade-offs for each.
Read the worked answer
Programming should be individualized and performed with the patient's VT history in mind.
First, raise the VT detection rate. If the maximum AF ventricular rate is consistently 175 bpm, a VT zone starting at about 190 bpm would avoid most AF while still treating the prior 180 bpm VT, although it would delay detection of that VT until it accelerates. Some clinicians would instead keep the zone at 160–170 bpm but enable stronger AF/AFL rejection, require more intervals to detect, and use ATP before shocks.
Second, enable and optimize SVT discrimination features: AF/AFL suppression, interval stability, onset, and morphology if available. Use ATP first in the VT zone, with shocks reserved for failed ATP or faster rhythms. Avoid programming a single high-rate VF-only zone unless the patient has no slow VT.
Third, address the trigger. Amiodarone may be contributing to bradycardia or proarrhythmia but is also suppressing VT; do not stop it without electrophysiology input. Add or optimize rate control (beta-blocker, digoxin, or calcium channel blocker as appropriate) and confirm anticoagulation, since AF with RVR and shocks increase risk. If AF remains refractory, AV node ablation with pacing may be considered, but it commits the patient to chronic ventricular pacing.
Finally, arrange remote monitoring and early follow-up after reprogramming to verify that AF no longer triggers detection.
3. What follow-up and patient education should be provided before discharge?
Read the worked answer
The patient should be told that the device was not malfunctioning but responded to a fast atrial rhythm, and that reprogramming reduces but does not eliminate the chance of inappropriate therapy. He should continue apixaban and rate-control medication, report palpitations, dizziness, or shocks promptly, and use the remote monitor as instructed.
A follow-up visit should occur within 2–4 weeks to review stored episodes and verify that AF is no longer entering the VT zone. The device should be interrogated after any shock, and the patient should know when to call emergency services (shock with syncope, multiple shocks, chest pain, or dyspnea). Avoid strong magnets near the device. If he develops frequent AF despite rate control, referral for AV node ablation or other rhythm control should be discussed.